
    
      This is a multi-center, randomized, double blind, placebo-controlled, single dose escalation
      study of the safety and tolerability of subcutaneously administered REGN88 in rheumatoid
      arthritis patients who are receiving concomitant methotrexate.

      Three (3) sequential dose cohorts of 5 subjects (4:1 active: placebo) will be dosed SC with
      REGN88 or placebo. Subjects who complete the study will participate in 14 study visits over
      16 weeks.
    
  